Co-Authors
This is a "connection" page, showing publications co-authored by SUDHAKAR TUMMALA and SATTVA S NEELAPU.
Connection Strength
0.560
-
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 04; 15(4):218.
Score: 0.156
-
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15(1):47-62.
Score: 0.151
-
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma. 2024 May; 65(5):669-673.
Score: 0.059
-
Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy. Int J Infect Dis. 2021 Nov; 112:327-329.
Score: 0.050
-
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.
Score: 0.049
-
Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica. 2021 05 01; 106(5):1504-1506.
Score: 0.049
-
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 08 25; 4(16):3943-3951.
Score: 0.046